The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance

BACKGROUND: Taxanes are routinely used for the treatment of prostate cancer, however the majority of patients eventually develop resistance. We investigated the potential efficacy of EL102, a novel toluidine sulphonamide, in pre-clinical models of prostate cancer. METHODS: The effect of EL102 and/or...

Descripción completa

Detalles Bibliográficos
Autores principales: Toner, A P, McLaughlin, F, Giles, F J, Sullivan, F J, O'Connell, E, Carleton, L A, Breen, L, Dunne, G, Gorman, A M, Lewis, J D, Glynn, S A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798953/
https://www.ncbi.nlm.nih.gov/pubmed/24052043
http://dx.doi.org/10.1038/bjc.2013.537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798953/
https://www.ncbi.nlm.nih.gov/pubmed/24052043
http://dx.doi.org/10.1038/bjc.2013.537

Ejemplares similares